Amylyx PharmaceuticalsAMLX -1.09%33 Current Ratio is 17.85 as of Mar. 2026, which is 137% above its 10-year median of 7.54. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 97.29% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Amylyx Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 17.85.
Amylyx Pharmaceuticals has a current ratio of 17.85. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Amylyx Pharmaceuticals's Current Ratio or its related term are showing as below:
AMLX'
s Current Ratio Range Over the Past 10 Years
Min: 0.71 Med: 7.54 Max: 17.85
Current: 17.85
During the past 7 years, Amylyx Pharmaceuticals's highest Current Ratio was 17.85. The lowest was 0.71. And the median was 7.54.
AMLX's Current Ratio is ranked better than 97.29% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs AMLX: 17.85
Amylyx Pharmaceuticals (NAS:AMLX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Amylyx Pharmaceuticals Current Ratio Related Terms
Amylyx Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMLX vs PRGO, ANIP, HROW: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (AMLX) has a Current Ratio of 17.85 as of Mar. 2026. This is 137% above median its historical median of 7.54. Over the past decade, Amylyx Pharmaceuticals' Current Ratio has ranged from 0.71 to 17.85. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #27 out of 998 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Amylyx Pharmaceuticals' Current Ratio too high?
Amylyx Pharmaceuticals' current Current Ratio of 17.85 is 137% above median its 10-year median of 7.54. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 17.85. The Drug Manufacturers industry median Current Ratio is 2.00. Amylyx Pharmaceuticals' value of 17.85 is 794.7% above this industry median. Based on the distribution chart, Amylyx Pharmaceuticals ranks #27 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Current Ratio compare to PRGO and ANIP?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #27 out of 998 companies for Current Ratio. This places Amylyx Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Amylyx Pharmaceuticals' value of 17.85 is 794.7% above this benchmark. Historically, Amylyx Pharmaceuticals' own Current Ratio has ranged from 0.71 to 17.85 over the past decade. While the company's 10-year median is 7.54 vs. the industry median of 2.00, Amylyx Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amylyx Pharmaceuticals's current Current Ratio of 17.85 is 794.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current Current Ratio is 17.85, which is 137% above median its own 10-year median of 7.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Current Ratio of 17.85. The current Current Ratio is 17.85, which is 137% above median its 10-year median of 7.54 and 794.7% above the Drug Manufacturers industry median of 2.00. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Current Ratio is 17.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
